Literature DB >> 17222605

Defining optimal therapy for muscle invasive bladder cancer.

Harry W Herr1, Zohar Dotan, S Machele Donat, Dean F Bajorin.   

Abstract

PURPOSE: We defined an optimal curative strategy for muscle invasive bladder cancer and to determine how best to deliver curative therapy.
MATERIALS AND METHODS: We reviewed published reports from 1985 to 2006 dealing with the treatment of muscle invasive (stage T2-T4a) bladder cancer. We analyzed all cohort, phase II and randomized phase III studies providing level 1 to 3 evidence impacting survival.
RESULTS: Cisplatin based chemotherapy combined with high quality radical cystectomy and complete pelvic lymph node dissection improves survival over that of cystectomy alone. Surgery quality is an important predictor of survival even in patients receiving chemotherapy. Neoadjuvant chemotherapy is favored over adjuvant chemotherapy because it is better tolerated and more patients are able to receive effective therapy before rather than after surgery.
CONCLUSIONS: Neoadjuvant chemotherapy followed by radical cystectomy and complete pelvic lymph node dissection is the optimal curative strategy in most patients presenting with muscle invasive bladder cancer.

Entities:  

Mesh:

Year:  2007        PMID: 17222605     DOI: 10.1016/j.juro.2006.09.027

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  60 in total

1.  Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma.

Authors:  Ying-Li Lin; Xiao-Qiang Liu; Wen-Ping Li; Guang Sun; Chun-Ting Zhang
Journal:  Int Urol Nephrol       Date:  2011-04-24       Impact factor: 2.370

2.  A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers.

Authors:  Garrett M Dancik; Yuanbin Ru; Charles R Owens; Dan Theodorescu
Journal:  Cancer Res       Date:  2011-10-19       Impact factor: 12.701

3.  Robotic radical cystectomy with intracorporeal neobladder: Initial experience and outcomes.

Authors:  Zulfiqar A Butt; Ellen Forbes; Jeff Zorn; Blair St Martin
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

Review 4.  Increasing utilization of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the United States.

Authors:  Kirk A Keegan; Harras B Zaid; Sanjay G Patel; Sam S Chang
Journal:  Curr Urol Rep       Date:  2014-04       Impact factor: 3.092

Review 5.  Urothelial carcinoma of the bladder: definition, treatment and future efforts.

Authors:  Sandip M Prasad; G Joel Decastro; Gary D Steinberg
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

6.  The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers.

Authors:  Igor Makhlin; Jiaru Zhang; Christopher J Long; Karthik Devarajan; Yan Zhou; Andres J Klein-Szanto; Min Huang; Jonathan Chernoff; Stephen A Boorjian
Journal:  BJU Int       Date:  2010-11-02       Impact factor: 5.588

7.  Quantitative risk stratification and individual comprehensive therapy for invasive bladder cancers in China.

Authors:  Hai Tao Niu; Haitao Niu; Shi Xiu Shao; Shixiu Shao; Zong Liang Zhang; Zongliang Zhang; Shuai Wu; Bo Cheng; De Quan Pang; Dequan Pang; Ya Jun E; Yajun E; Sheng Guo Dong; Shengguo Dong; Guang Sun; Ji Wu Chang; Jiwu Chang
Journal:  Int Urol Nephrol       Date:  2008-09-23       Impact factor: 2.370

Review 8.  [Systemic oncological treatment of bladder cancer].

Authors:  Johannes Gobertus Meran; Stefan Kudlacek; Dora Beke
Journal:  Wien Med Wochenschr       Date:  2007

Review 9.  Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?

Authors:  Samir P Shirodkar; Vinata B Lokeshwar
Journal:  Expert Rev Anticancer Ther       Date:  2008-07       Impact factor: 4.512

10.  Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.

Authors:  Kristi L Hoffman; Seth P Lerner; Carolyn L Smith
Journal:  Horm Cancer       Date:  2012-09-11       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.